Rifaximin: In vitro and in vivo antibacterial activity - A review

被引:115
作者
Jiang, ZD
DuPont, HL
机构
[1] Univ Texas, Sch Publ Hlth, Ctr Infect Dis, Houston, TX 77030 USA
[2] St Lukes Episcopal Hosp, Houston, TX 77030 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
关键词
rifaximin; antibacterial activity; Gram-positive bacteria; Gram-negative bacteria;
D O I
10.1159/000081991
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In vitro inhibitory activity of rifaximin is directed against Gram-positive and Gram-negative, aerobic and anaerobic bacteria. It is effective in the treatment of gastrointestinal infections when given orally because of the high concentration of the drug remaining in the gut lumen. Laboratory investigations have been carried out to assess the in vitro activity of rifaximin on different bacterial strains isolated from both human and domestic animals. The objective of this project is to review the in vitro and in vivo activity of rifaximin against bacterial infection with Gram-negative rods, Gram-positive rods and Gram-positive cocci and their resistance to rifaximin. The available data suggest that rifaximin is active in vitro and in vivo in the treatment of bacterial infection of adults and children. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 37 条
[1]   Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world [J].
Adachi, JA ;
Jiang, ZD ;
Mathewson, JJ ;
Verenkar, MP ;
Thompson, S ;
Martinez-Sandoval, F ;
Steffen, R ;
Ericsson, CD ;
DuPont, HL .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (12) :1706-1709
[2]   Intestinal protozoa in HIV-infected patients:: Effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections [J].
Amenta, M ;
Dalle Nogare, ER ;
Colomba, C ;
Prestileo, TS ;
Di Lorenzo, F ;
Fundarò, S ;
Colomba, A ;
Ferrieri, A .
JOURNAL OF CHEMOTHERAPY, 1999, 11 (05) :391-395
[3]   Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis [J].
Brigidi, P ;
Swennen, E ;
Rizzello, F ;
Bozzolasco, M ;
Matteuzzi, D .
JOURNAL OF CHEMOTHERAPY, 2002, 14 (03) :290-295
[4]   TREATMENT OF SMALL-INTESTINE BACTERIAL OVERGROWTH WITH RIFAXIMIN, A NON-ABSORBABLE RIFAMYCIN [J].
CORAZZA, GR ;
VENTRUCCI, M ;
STROCCHI, A ;
SORGE, M ;
PRANZO, L ;
PEZZILLI, R ;
GASBARRINI, G .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1988, 16 (04) :312-316
[5]   BIOCHEMICAL-MECHANISMS OF HEPATIC-ENCEPHALOPATHY [J].
CROSSLEY, IR ;
WARDLE, EN ;
WILLIAMS, R .
CLINICAL SCIENCE, 1983, 64 (03) :247-252
[6]  
DELEO C, 1986, DRUG EXP CLIN RES, V12, P979
[7]  
Dell'Anna A, 1999, Eur Rev Med Pharmacol Sci, V3, P105
[8]   ORAL AZTREONAM, A POORLY ABSORBED YET EFFECTIVE THERAPY FOR BACTERIAL DIARRHEA IN UNITED-STATES TRAVELERS TO MEXICO [J].
DUPONT, HL ;
ERICSSON, CD ;
MATHEWSON, JJ ;
DELACABADA, FJ ;
CONRAD, DA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (14) :1932-1935
[9]   Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci [J].
DuPont, HL ;
Jiang, ZD .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (11) :1009-1011
[10]   TREATMENT OF TRAVELERS DIARRHEA WITH TRIMETHOPRIM SULFAMETHOXAZOLE AND WITH TRIMETHOPRIM ALONE [J].
DUPONT, HL ;
REVES, RR ;
GALINDO, E ;
SULLIVAN, PS ;
WOOD, LV ;
MENDIOLA, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (14) :841-844